### ü´Ä Cardiology: Atrial Fibrillation ECG Identification

#### ‚úÖ True Statements
1. An **irregularly irregular rhythm** on electrocardiogram (ECG) with **no discernible P waves** is characteristic of **atrial fibrillation**.
2. **Atrial flutter** typically demonstrates a **sawtooth pattern** with **inverted flutter waves** in **leads II, III, and aVF** and **positive flutter waves** in **lead V1**.
3. **Atrioventricular nodal reentrant tachycardia (AVNRT)** is typically characterized by a **short RP interval** and a **retrograde P wave** inscribed very close to the **QRS complex**.
4. **Atrioventricular reciprocating tachycardia (AVRT)** typically shows **shortening of the PR interval** and **slurring of the initial QRS complex** due to conduction over an **accessory pathway**.

#### üí¨ Extra
1. These ECG features distinguish atrial fibrillation from other supraventricular tachyarrhythmias.
2. AVNRT and AVRT are common forms of **paroxysmal supraventricular tachycardia (PSVT)** but have more regular rhythm patterns.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #Electrocardiography #Arrhythmia #AtrialFibrillation #ECG

#### üìö Reference
MKSAP 19: Cardiovascular Medicine ‚Äî Arrhythmias, Atrial Fibrillation, Diagnosis

#### üÜî Question ID
CVVDX24004

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Arrhythmias, *Atrial Fibrillation*

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Atrial fibrillation (AF)** is the **most common sustained cardiac arrhythmia** encountered in clinical practice.
2. The **lifetime probability of developing AF is about 25 % for individuals older than 40 years**, and the annual incidence of AF increases steadily with age.
3. AF confers an **independent elevation in risk for ischemic stroke, incident heart failure, and dementia**.
4. Long-standing **modifiable risk factors** for AF include **diabetes mellitus, cigarette smoking, heavy alcohol consumption, obesity, hypertension, coronary artery disease (CAD), heart failure, and obstructive sleep apnea**.
5. Structured **lifestyle-modification programs** that promote **greater physical activity, intentional weight loss, smoking cessation, and abstinence from alcohol** reduce incident AF in at-risk populations.
6. **Routine caffeine restriction is unnecessary** for primary prevention of atrial fibrillation.
7. **Bariatric (weight-loss) surgery** reduces arrhythmia burden and should be considered in **eligible obese patients** to lower future AF risk.
8. **Optimal control of blood pressure, improvement in glycemic control, and treatment of obstructive sleep apnea** each decrease the likelihood of incident AF.
9. Acute or reversible precipitants of AF include **pulmonary embolism, severe critical illness (e.g., sepsis), and untreated hyperthyroidism**.
10. When no modifiable triggers are identified, a **heritable genetic predisposition** is often present in new-onset AF.
11. **Post-operative AF** occurring within days of cardiac surgery is common, usually reversible, and does **not necessarily predict progression to chronic AF**.
12. The symptom spectrum of AF ranges from **asymptomatic** to **palpitations, light-headedness, dizziness, dyspnea, exercise intolerance, fatigue, chest pain, near-syncope, or syncope**.
13. AF can precipitate **acute hemodynamic compromise** in patients with **advanced diastolic dysfunction or restrictive cardiomyopathy**.
14. **Persistent rapid ventricular response** during AF can cause **tachycardia-induced cardiomyopathy** or precipitate overt heart failure.
15. Among adults aged **‚â• 55 years** who experience an **ischemic stroke or transient ischemic attack of undetermined source**, occult AF is present in **up to 25 % of cases**.
16. **Fourteen- to 30-day continuous ambulatory ECG monitoring** is recommended after cryptogenic stroke to detect previously unrecognized AF.
17. If extended ambulatory monitoring fails to identify AF, **implantation of a subcutaneous loop recorder** is reasonable for longer-term rhythm surveillance.
18. **Evidence is lacking** that empiric anticoagulation improves outcomes solely on the basis of **silent AF discovered after cryptogenic stroke**.
19. Clinical staging of AF recognizes **paroxysmal, persistent, long-standing persistent, and permanent** forms, reflecting a progressive disease continuum.
20. **Paroxysmal AF** terminates spontaneously within **7 days** of onset, whereas **persistent AF** lasts **‚â• 7 days or requires cardioversion** to restore sinus rhythm.
21. **Long-standing persistent AF** is continuous for **> 1 year**, and **permanent AF** describes cases in which both physician and patient have decided to abandon rhythm-control efforts.
22. Every newly diagnosed AF patient should undergo **thyroid-stimulating hormone testing** to screen for **hyperthyroidism**.
23. **Transthoracic echocardiography** is indicated at AF diagnosis to evaluate **cardiac structure, ventricular function, valvular disease, and left-atrial size**.
24. Patients with risk factors for or symptoms suggestive of **obstructive sleep apnea** should undergo formal sleep testing after an AF diagnosis.
25. **Urgent electrical or pharmacologic cardioversion** is indicated when AF with rapid ventricular response causes **hypotension, acute myocardial ischemia, or decompensated heart failure**.
26. For AF or flutter of **> 48 hours duration (or unknown duration)** requiring immediate cardioversion, **therapeutic anticoagulation must begin promptly and continue for ‚â• 4 weeks**.
27. In hemodynamically **stable AF**, primary therapeutic goals are **stroke prevention, ventricular-rate control, symptom relief, and modification of underlying risk factors**.
28. When elective cardioversion is planned and AF duration is **< 48 hours**, **pre- and post-procedural anticoagulation** is recommended for **men with CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 2 and women with CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 3**.
29. If AF duration is **> 48 hours or uncertain**, at least **3 weeks of therapeutic anticoagulation** is recommended before cardioversion.
30. **Transesophageal echocardiography, contrast-enhanced cardiac CT, or cardiac MRI** can rule out **left-atrial-appendage thrombus** and allow expedited cardioversion in anticoagulated patients.
31. All patients with AF of **‚â• 48 hours duration or unknown duration** who undergo cardioversion must **continue anticoagulation for ‚â• 4 weeks** post-procedure.
32. The immediate target **ventricular-rate goal** in acute AF management is **60 ‚Äì 110 beats min‚Åª¬π**.
33. **Intravenous or oral Œ≤-blockers** and **non-dihydropyridine calcium-channel blockers (diltiazem, verapamil)** are first-line agents for acute ventricular-rate control in AF.
34. **Non-dihydropyridine calcium-channel blockers** should be **avoided** for rate control in AF patients with **left-ventricular systolic dysfunction (LVEF < 50 %)**.
35. **Digoxin** is useful as **adjunctive therapy** to improve rate control in AF, particularly in patients with **heart failure or low blood pressure**.
36. **Arterial thromboembolism** is the most serious complication of AF and may occur in **paroxysmal, persistent, or permanent** forms of the arrhythmia.
37. In **non-valvular AF**, the presence of **heart failure, hypertension, diabetes mellitus, or vascular disease** increases thromboembolism risk **\~15‚Äì20-fold**.
38. The **CHA‚ÇÇDS‚ÇÇ-VASc score** should guide anticoagulation in non-valvular AF but is **not applicable** to **valvular AF** (moderate/severe mitral stenosis or mechanical valve) or **hypertrophic cardiomyopathy**.
39. The **2023 ACC/AHA/HRS focused update** recommends chronic oral anticoagulation for non-valvular AF when **CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 2 in men or ‚â• 3 in women**, while allowing additional factors (e.g., chronic kidney disease) to influence decisions.
40. **American College of Chest Physicians guidelines** suggest initiating anticoagulation in non-valvular AF when **‚â• 1 non-sex stroke-risk factor is present** (CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 1 in men or ‚â• 2 in women).
41. **Antiplatelet monotherapy** (e.g., aspirin alone) is **no longer recommended** for primary stroke prevention in AF.
42. In eligible patients with non-valvular AF, **direct oral anticoagulants (DOACs)** are **preferred over warfarin** for stroke prevention.
43. **Warfarin** remains the anticoagulant of choice for **valvular AF** associated with **moderate-to-severe mitral stenosis or mechanical prosthetic heart valves**.
44. The effectiveness and safety of warfarin depend on maintaining an **INR of 2.0‚Äì3.0**, necessitating **regular laboratory monitoring and dose adjustment**.
45. Four DOACs‚Äî**dabigatran (direct thrombin inhibitor)** and the factor-Xa inhibitors **rivaroxaban, apixaban, and edoxaban**‚Äîare approved for stroke prevention in AF.
46. **Dabigatran and rivaroxaban** are associated with **higher gastrointestinal-bleeding rates** than warfarin, and **dabigatran** can cause **dyspepsia**.
47. Life-threatening bleeding from factor-Xa inhibitors should be treated with **andexanet alfa** or, if unavailable, **four-factor prothrombin-complex concentrate**.
48. **Idarucizumab** is a monoclonal antibody fragment that **rapidly reverses dabigatran** anticoagulation in emergencies.
49. **Baseline and annual assessment of renal and hepatic function** is required when prescribing any DOAC.
50. In AF patients who undergo **PCI for acute coronary syndrome** and have **CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 2**, **triple therapy** (oral anticoagulant + aspirin + P2Y‚ÇÅ‚ÇÇ inhibitor) is recommended for **1‚Äì4 weeks**.
51. After a short course of triple therapy, **dual therapy** with a **DOAC plus a P2Y‚ÇÅ‚ÇÇ inhibitor** (usually clopidogrel or ticagrelor) is preferred to reduce bleeding risk.
52. In AF with **stable CAD ‚â• 1 year post-PCI**, **oral anticoagulation alone** may be sufficient for secondary prevention.
53. For AF patients receiving **two or more antithrombotic agents**, **proton-pump-inhibitor therapy** is recommended and **NSAIDs should be avoided** to minimize gastrointestinal-bleeding risk.
54. In patients with AF and **stable CAD**, **rivaroxaban monotherapy** is non-inferior to rivaroxaban + aspirin for ischemic prevention and causes **less bleeding**.
55. Standard management of AF prioritizes **effective ventricular-rate control**, targeting a resting heart rate **< 80 beats min‚Åª¬π** in symptomatic patients and **< 110 beats min‚Åª¬π** in asymptomatic patients without LV dysfunction.
56. A **rhythm-control strategy** offers additional benefit in AF patients who are **younger, symptomatic, within 1 year of diagnosis, or have heart failure with reduced ejection fraction**.
57. The **EAST-AFNET 4 trial** showed that initiating rhythm-control therapy **within 1 year of AF diagnosis** reduced cardiovascular death, stroke, and hospitalization versus usual care.
58. **Catheter ablation (pulmonary-vein isolation)** is more effective than antiarrhythmic drugs for maintaining sinus rhythm and may be considered **first-line therapy** in selected symptomatic AF patients without significant left-atrial enlargement.
59. Regardless of sinus-rhythm maintenance after successful ablation, **long-term anticoagulation decisions** should continue to be guided by the **CHA‚ÇÇDS‚ÇÇ-VASc score**.
60. **Periprocedural risks of AF ablation** include thromboembolism (0.5 ‚Äì 1 %), cardiac tamponade, and access-site vascular injury; **pulmonary-vein stenosis** is a rare late complication.
61. In AF patients with **refractory symptomatic tachycardia**, **AV-node ablation plus permanent pacemaker implantation** can control ventricular rate, but **lifelong anticoagulation remains mandatory**.
62. Approximately **10‚Äì25 % of AF patients** have contraindications to long-term oral anticoagulation; for those with **CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 3 and bleeding concerns**, **left-atrial-appendage occlusion (LAAO)** offers an alternative stroke-prevention strategy.
63. After percutaneous **LAAO**, most patients require **short-term anticoagulation** followed by **long-term antiplatelet therapy** while the device endothelializes.
64. **LAAO** carries ongoing risks of **peri-device leak** and **device-related thrombus**, and no consensus exists on routine post-procedure imaging surveillance.
65. **AF coexists with heart failure in roughly 40 % of cases**, and the combination markedly worsens morbidity and mortality.
66. Randomized trials show that **aggressive rhythm control** in patients with **AF and concomitant heart failure** improves symptoms, decreases hospitalization, and reduces mortality.
67. In **heart failure with reduced ejection fraction**, **catheter ablation of AF** yields superior outcomes compared with antiarrhythmic-drug therapy in appropriately selected patients.
68. **Subclinical (device-detected) AF** is defined as **asymptomatic atrial tachyarrhythmia lasting ‚â• 20 seconds but < 24 hours**, increasingly recognized with implantable rhythm devices and consumer wearables.
69. Because subclinical AF often progresses to clinically apparent arrhythmia, **guideline-directed lifestyle modification and risk-factor control** are advisable even in asymptomatic individuals.
70. Current guidelines recommend **oral anticoagulation** for **device-detected AF lasting ‚â• 24 hours with CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 2** or for **episodes lasting 5 minutes ‚Äì 24 hours with CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 3**.
71. In **embolic stroke of undetermined source**, any device-detected AF episode **> 30 seconds** justifies initiation of oral anticoagulation.
72. When ambulatory monitoring fails to reveal AF after cryptogenic stroke, **implantation of an insertable loop recorder** is indicated to facilitate long-term detection of subclinical arrhythmia.

---

#### üí¨ Extra

1. *‚ÄúSustained‚Äù arrhythmia refers to an episode that lasts ‚â• 30 seconds or requires intervention for termination.*
2. *Incidence roughly doubles with each additional decade of life after age 50.*
3. *Meta-analyses show a \~5-fold increase in stroke risk in untreated AF.*
4. *Obstructive sleep apnea is linked to both incident AF and recurrence after ablation.*
5. *Weight loss > 10 % can reduce arrhythmia-free recurrence by ‚âà 45 %.*
6. *Observational studies have not demonstrated a consistent association between caffeine and new-onset AF.*
7. *Bariatric surgery reduces AF burden even after adjusting for weight loss alone.*
8. *Treatment of sleep apnea with CPAP lowers AF recurrence post-cardioversion.*
9. *Thyrotoxicosis should be corrected to restore and maintain sinus rhythm.*
10. *First-degree relatives of early-onset AF patients have a two- to three-fold increased risk.*
11. *Post-operative AF incidence peaks between 2 ‚Äì 4 days after cardiac surgery.*
12. *Asymptomatic AF is often discovered during routine ECGs or device interrogation.*
13. *Loss of atrial kick plus rapid rate reduces diastolic filling and cardiac output.*
14. *Tachycardia-induced cardiomyopathy typically resolves after rate or rhythm control.*
15. *Cryptogenic strokes account for ‚âà 25 % of all ischemic strokes.*
16. *Mobile cardiac telemetry is superior to Holter for detecting paroxysmal AF.*
17. *Loop recorders detect AF in up to 30 % of patients within 3 years.*
18. *Ongoing trials are examining whether treating device-detected AF changes outcomes.*
19. *Progression rates: paroxysmal ‚Üí persistent ‚âà 5‚Äì10 % per year.*
20. *Cessation of antiarrhythmic drugs can be considered after ‚â• 2 months of stable sinus rhythm in paroxysmal AF.*
21. *The term ‚Äúpermanent‚Äù does not preclude future rhythm-control attempts if circumstances change.*
22. *Hyperthyroidism shortens atrial refractory periods, facilitating AF.*
23. *Left-atrial enlargement predicts failure of rhythm-control strategies.*
24. *Sleep apnea treatment improves rhythm-control success rates.*
25. *Immediate cardioversion without anticoagulation is reasonable only for AF < 12 h with very low CHA‚ÇÇDS‚ÇÇ-VASc.*
26. *Early anticoagulation mitigates atrial stunning and thrombus formation after cardioversion.*
27. *Risk-factor modification includes alcohol reduction to ‚â§ 1 drink/day for women and ‚â§ 2 for men.*
28. *Cardioversion success rates exceed 90 % when AF duration < 48 h.*
29. *TEE-guided early cardioversion avoids delay but still requires ‚â• 4 weeks of anticoagulation.*
30. *Cardiac MRI offers additional information on atrial fibrosis and cardiomyopathy.*
31. *Thromboembolic risk remains high in the first 30 days post-cardioversion.*
32. *Lenient rate control (< 110 bpm) is acceptable in asymptomatic patients without LV dysfunction.*
33. *Esmolol provides rapid, titratable Œ≤-blockade for acute control.*
34. *Diltiazem and verapamil depress myocardial contractility at higher doses.*
35. *Digoxin is less effective during exertion because of sympathetic activation.*
36. *AF accounts for ‚âà 20 % of all ischemic strokes.*
37. *CHA‚ÇÇDS‚ÇÇ-VASc ‚â• 9 corresponds to an annual stroke risk > 15 %.*
38. *Mitral stenosis causes stasis in the left atrium, necessitating anticoagulation independent of score.*
39. *Chronic kidney disease stage ‚â• 3 adds \~1 point equivalent risk by guideline consensus.*
40. *ACC-Chest differences reflect varying tolerance for bleeding versus stroke risk.*
41. *Dual antiplatelet therapy is inferior to oral anticoagulation for stroke prevention in AF.*
42. *DOACs have fewer food-drug interactions than warfarin.*
43. *Mechanical valves create high shear stress that inactivates DOACs.*
44. *Time in therapeutic range > 70 % is required to match DOAC efficacy.*
45. *Edoxaban should be avoided when CrCl > 95 mL/min due to reduced efficacy.*
46. *Proton-pump-inhibitor prophylaxis mitigates GI bleeding with dabigatran.*
47. *4F-PCC dosing is weight-based (50 IU kg‚Åª¬π) for Xa-inhibitor reversal.*
48. *Idarucizumab normalizes dilute thrombin time within minutes.*
49. *CrCl < 15 mL/min is a contraindication for most DOACs.*
50. *Triple therapy durations beyond 4 weeks increase major-bleeding risk without ischemic benefit.*
51. *Ticagrelor is preferred to clopidogrel in ACS with high on-clopidogrel platelet reactivity.*
52. *After the first year, bleeding outweighs ischemic benefit from antiplatelet addition.*
53. *NSAID use increases GI bleed risk 3-fold in anticoagulated patients.*
54. *COMPASS-style low-dose rivaroxaban plus aspirin has not been studied in AF.*
55. *Heart-rate assessment during activity (e.g., 6-min walk) ensures adequate control.*
56. *Early rhythm control may reduce atrial remodeling and disease progression.*
57. *Median time to therapy initiation in EAST-AFNET 4 was 36 days from diagnosis.*
58. *Cryoballoon and radio-frequency are the two dominant ablation energy sources.*
59. *CHA‚ÇÇDS‚ÇÇ-VASc reassessment is advised annually post-ablation.*
60. *Pericardial tamponade rate is ‚âà 1/500 procedures in high-volume centers.*
61. *AV-node ablation yields near-100 % ventricular-rate control but creates pacemaker dependence.*
62. *Watchman FLX and Amplatzer Amulet are the two FDA-approved LAAO devices.*
63. *Typical post-LAAO regimen: DOAC √ó 45 days ‚Üí clopidogrel + aspirin √ó 6 months ‚Üí aspirin lifelong.*
64. *Device-related thrombus occurs in ‚âà 3 % of LAAO implants and mandates anticoagulation.*
65. *AF-related loss of atrial contraction exacerbates pulmonary congestion in heart failure.*
66. *CASTLE-AF trial showed mortality benefit from ablation in HFrEF with AF.*
67. *Success of AF ablation in HFrEF correlates inversely with left-atrial diameter.*
68. *Consumer devices detect AF via photoplethysmography or single-lead ECG algorithms.*
69. *Lifestyle counseling mirrors recommendations for overt AF (weight, BP, alcohol).*
70. *Evidence base for anticoagulating subclinical AF derives partly from NOAH-AFNET 6.*
71. *Cryptogenic strokes are often embolic and of undetermined source (ESUS) by definition.*
72. *Loop recorders can store episodes for clinician review for up to 3 years.*

---

### üìä Supplemental Figures and Tables for Atrial Fibrillation

#### üñºÔ∏è Figure: ECG Demonstrating Atrial Fibrillation
<img src="ECG Demonstrating Atrial Fibrillation.jpg" alt="ECG showing atrial fibrillation" style="max-width:100%;height:auto;">
<br>
<em>No clear P waves are seen, and the ventricular response is irregular.</em>

---

#### üóÇÔ∏è Table 1. CHA<sub>2</sub>DS<sub>2</sub>-VASc Score, Adjusted Stroke Rates, and Stroke Prevention Therapy Recommendations for Nonvalvular Atrial Fibrillation and Flutter

<table>
  <caption><strong>CHA<sub>2</sub>DS<sub>2</sub>-VASc Score, Adjusted Stroke Rates, and Stroke Prevention Therapy Recommendations for Nonvalvular Atrial Fibrillation and Flutter</strong></caption>
  <thead>
    <tr>
      <th>CHA<sub>2</sub>DS<sub>2</sub>-VASc Score<sup>a</sup></th>
      <th>Incidence of Ischemic Stroke/100 Patient-Years<sup>b</sup></th>
      <th colspan="2">Stroke Prevention Therapy<sup>c</sup></th>
    </tr>
    <tr>
      <th></th>
      <th></th>
      <th>Men</th>
      <th>Women</th>
    </tr>
  </thead>
  <tbody>
    <tr><td>0</td><td>0.2</td><td>None</td><td>N/A</td></tr>
    <tr><td>1</td><td>0.6</td><td>Consider OAC</td><td>None</td></tr>
    <tr><td>2</td><td>2.2</td><td>OAC</td><td>Consider OAC</td></tr>
    <tr><td>3</td><td>3.2</td><td>OAC</td><td>OAC</td></tr>
    <tr><td>4</td><td>4.8</td><td>OAC</td><td>OAC</td></tr>
    <tr><td>5</td><td>7.2</td><td>OAC</td><td>OAC</td></tr>
    <tr><td>6+</td><td>10.3</td><td>OAC</td><td>OAC</td></tr>
  </tbody>
</table>
<p><small>N/A = not applicable; OAC = oral anticoagulation.</small></p>
<p><small><sup>a</sup>CHA<sub>2</sub>DS<sub>2</sub>-VASc scoring (maximum 9 points): One point each is given for heart failure, hypertension, diabetes mellitus, vascular disease (prior myocardial infarction, peripheral artery disease, aortic plaque), female sex, and age 65 to 74 years. Two points each are given for previous stroke/transient ischemic attack/thromboembolic disease and age ‚â•75 years.</small></p>
<p><small><sup>b</sup>Data from Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500‚Äì10. <a href="https://pubmed.ncbi.nlm.nih.gov/22246443" target="_blank">PMID: 22246443</a></small></p>
<p><small><sup>c</sup>Recommendations from Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <em>Circulation</em>. 2024;149:e1‚Äìe156. <a href="https://pubmed.ncbi.nlm.nih.gov/38033089" target="_blank">PMID: 38033089</a></small></p>

---

#### üóÇÔ∏è Table 2. Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation

<table>
  <caption><strong>Anticoagulants Approved for Stroke Prevention in Atrial Fibrillation</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Frequency</th>
      <th>Type of AF</th>
      <th>Cautions and Dosing</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warfarin (vitamin K antagonist)</td>
      <td>Dose adjusted to INR</td>
      <td>Valvular<sup>a</sup> or nonvalvular</td>
      <td>
        Avoid in pregnancy<br>
        Caution with idiopathic thrombocytopenic purpura, heparin-induced thrombocytopenia, liver disease, protein C or S deficiency<br>
        Many drug and food interactions
      </td>
    </tr>
    <tr>
      <td>Dabigatran<br>(direct thrombin inhibitor)</td>
      <td>Twice daily</td>
      <td>Nonvalvular</td>
      <td>
        Caution with use of P-glycoprotein inhibitors<br>
        Reduce dosage with CrCl 15‚Äì30 mL/min/1.73 m<sup>2</sup>
      </td>
    </tr>
    <tr>
      <td>Rivaroxaban<br>(factor Xa inhibitor)</td>
      <td>Once daily</td>
      <td>Nonvalvular</td>
      <td>
        Avoid with CrCl &lt;30 mL/min/1.73 m<sup>2</sup>, moderate liver impairment, use of strong P-glycoprotein inhibitors, or use of strong cytochrome P-450 inducers and inhibitors<br>
        Reduce dosage with CrCl 30‚Äì50 mL/min/1.73 m<sup>2</sup>
      </td>
    </tr>
    <tr>
      <td>Apixaban<br>(factor Xa inhibitor)</td>
      <td>Twice daily</td>
      <td>Nonvalvular</td>
      <td>
        Avoid with use of strong P-glycoprotein inhibitors or strong cytochrome P-450 inducers and inhibitors<br>
        Reduce dosage with two of the following criteria: creatinine level ‚â•1.5 mg/dL (133 Œºmol/L), age ‚â•80 y, or weight ‚â§60 kg (132 lb)
      </td>
    </tr>
    <tr>
      <td>Edoxaban<br>(factor Xa inhibitor)</td>
      <td>Once daily</td>
      <td>Nonvalvular</td>
      <td>
        Avoid with use of strong cytochrome P-450 inducers and inhibitors<br>
        Avoid with CrCl &gt;95 mL/min/1.73 m<sup>2</sup> (reduced stroke prevention effectiveness).<br>
        Reduce dosage with CrCl 30‚Äì50 mL/min/1.73 m<sup>2</sup>, weight ‚â§60 kg (132 lb), or concomitant use of verapamil or quinidine (potent P-glycoprotein inhibitors)
      </td>
    </tr>
  </tbody>
</table>
<p><small>AF = atrial fibrillation; CrCl = creatinine clearance.</small><br>
<small><sup>a</sup>Valvular AF refers to AF in the presence of moderate to severe mitral stenosis or mechanical valve prosthesis.</small></p>


---

#### üóÇÔ∏è Table 3. Factors Favoring Rhythm vs. Rate Control of Atrial Fibrillation

<table>
  <caption><strong>Factors Favoring Rhythm Versus Rate Control of Atrial Fibrillation</strong></caption>
  <thead>
    <tr>
      <th>Favors Rhythm Control</th>
      <th>Favors Rate Control</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Young age</td>
      <td>Long-standing, persistent AF</td>
    </tr>
    <tr>
      <td>Relatively recent AF diagnosis (&lt;1 year)</td>
      <td>Comorbid condition that increases the risk of rhythm control therapies (e.g., very advanced age, severe noncardiac disease)</td>
    </tr>
    <tr>
      <td>Concomitant heart failure</td>
      <td>Contraindications to rhythm control medications</td>
    </tr>
    <tr>
      <td>Highly symptomatic or poor health-related quality of life related to AF</td>
      <td>Absence of symptoms, with structurally normal heart</td>
    </tr>
    <tr>
      <td>Failure of rate control to improve symptoms, functional status, or structural heart disease</td>
      <td>Failure of several previous attempts at rhythm control</td>
    </tr>
    <tr>
      <td>High risk for adverse events related to AF<sup>a</sup></td>
      <td></td>
    </tr>
  </tbody>
</table>
<p><small>AF = atrial fibrillation.</small></p>
<p><small><sup>a</sup>Such as patients included in the EAST-AFNET 4 trial: age older than 75 years or a previous transient ischemic attack or stroke, or meeting two of the following criteria: age older than 65 years, female sex, heart failure, hypertension, diabetes, severe coronary artery disease, chronic kidney disease, and left ventricular hypertrophy.</small></p>
